KPC Pharmaceuticals,Inc. (SHA:600422)
China · Delayed Price · Currency is CNY 9.50
+0.01 (0.11%)
Apr 29, 2026, 3:00 PM CST
KPC Pharmaceuticals,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,500 | 6,272 | 7,960 | 8,266 | 7,720 | 8,045 |
Other Revenue | 303.38 | 303.38 | 441.93 | 163.98 | 562.24 | 208.77 |
| 5,803 | 6,575 | 8,401 | 8,430 | 8,282 | 8,254 | |
Revenue Growth (YoY) | -28.21% | -21.74% | -0.34% | 1.79% | 0.35% | 6.95% |
Cost of Revenue | 3,696 | 4,063 | 4,771 | 4,544 | 4,855 | 4,865 |
Gross Profit | 2,107 | 2,512 | 3,631 | 3,886 | 3,427 | 3,389 |
Selling, General & Admin | 1,984 | 2,087 | 2,597 | 2,983 | 2,812 | 2,779 |
Research & Development | 95.46 | 102.55 | 106.76 | 94.2 | 69.65 | 100.52 |
Other Operating Expenses | 62.4 | 50.29 | 65.04 | 68.06 | -57.25 | 64.56 |
Operating Expenses | 2,147 | 2,244 | 2,814 | 3,189 | 2,864 | 2,980 |
Operating Income | -39.17 | 268.1 | 816.64 | 696.42 | 563.54 | 409.19 |
Interest Expense | -50.59 | -50.59 | -26.36 | -21.61 | -40.73 | -33.59 |
Interest & Investment Income | 91.64 | 72.01 | 27.78 | 38.14 | 12.05 | 156.1 |
Currency Exchange Gain (Loss) | -0.23 | -0.23 | 1.92 | 2.08 | 3.08 | -3.48 |
Other Non Operating Income (Expenses) | -49.69 | -18.75 | 3.78 | -9.03 | -27.97 | -7.25 |
EBT Excluding Unusual Items | -48.04 | 270.54 | 823.75 | 705.99 | 509.97 | 520.97 |
Impairment of Goodwill | -4.1 | -4.1 | - | - | - | - |
Gain (Loss) on Sale of Investments | 149.5 | 108.91 | 6.92 | 1.03 | 10.67 | -0.96 |
Gain (Loss) on Sale of Assets | 1.11 | 0.67 | 1.01 | 1.04 | 15.21 | 2.2 |
Asset Writedown | -19.01 | -9.17 | -2.04 | -30.12 | -57.73 | -0.29 |
Other Unusual Items | 106.69 | 106.69 | 104.93 | 108.45 | -0.84 | 109.37 |
Pretax Income | 186.16 | 473.56 | 934.57 | 786.38 | 477.29 | 631.29 |
Income Tax Expense | 25.51 | 54.5 | 183.35 | 143.7 | 91.83 | 118.07 |
Earnings From Continuing Operations | 160.65 | 419.05 | 751.22 | 642.67 | 385.46 | 513.21 |
Minority Interest in Earnings | -42.98 | -69.11 | -103.14 | -101.96 | -2.28 | -5.55 |
Net Income | 117.67 | 349.94 | 648.08 | 540.71 | 383.18 | 507.67 |
Net Income to Common | 117.67 | 349.94 | 648.08 | 540.71 | 383.18 | 507.67 |
Net Income Growth | -80.62% | -46.00% | 19.86% | 41.11% | -24.52% | 11.12% |
Shares Outstanding (Basic) | 759 | 761 | 754 | 762 | 751 | 758 |
Shares Outstanding (Diluted) | 759 | 761 | 754 | 762 | 751 | 758 |
Shares Change (YoY) | 1.30% | 0.95% | -1.05% | 1.36% | -0.84% | -0.19% |
EPS (Basic) | 0.16 | 0.46 | 0.86 | 0.71 | 0.51 | 0.67 |
EPS (Diluted) | 0.16 | 0.46 | 0.86 | 0.71 | 0.51 | 0.67 |
EPS Growth | -80.87% | -46.51% | 21.13% | 39.22% | -23.88% | 11.33% |
Free Cash Flow | -294.61 | 198.68 | 728.63 | 644.69 | 152.15 | 15.46 |
Free Cash Flow Per Share | -0.39 | 0.26 | 0.97 | 0.85 | 0.20 | 0.02 |
Dividend Per Share | 0.180 | 0.180 | 0.300 | 0.200 | 0.160 | 0.270 |
Dividend Growth | -40.00% | -40.00% | 50.00% | 25.00% | -40.74% | 17.39% |
Gross Margin | 36.31% | 38.21% | 43.22% | 46.10% | 41.38% | 41.06% |
Operating Margin | -0.68% | 4.08% | 9.72% | 8.26% | 6.80% | 4.96% |
Profit Margin | 2.03% | 5.32% | 7.71% | 6.41% | 4.63% | 6.15% |
Free Cash Flow Margin | -5.08% | 3.02% | 8.67% | 7.65% | 1.84% | 0.19% |
EBITDA | 116.67 | 427.67 | 991.12 | 871.81 | 744.03 | 568.04 |
EBITDA Margin | 2.01% | 6.50% | 11.80% | 10.34% | 8.98% | 6.88% |
D&A For EBITDA | 155.84 | 159.57 | 174.48 | 175.4 | 180.49 | 158.86 |
EBIT | -39.17 | 268.1 | 816.64 | 696.42 | 563.54 | 409.19 |
EBIT Margin | -0.68% | 4.08% | 9.72% | 8.26% | 6.80% | 4.96% |
Effective Tax Rate | 13.70% | 11.51% | 19.62% | 18.27% | 19.24% | 18.70% |
Revenue as Reported | 6,575 | 6,575 | 8,401 | 8,430 | 8,282 | 8,254 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.